Research Library

Recombinant protein expression is a fundamental technique that underpins clinical diagnostics, drug discovery and screening, vaccine development, and pure research for elucidating mechanisms of disease development and progression. However, high-throughput production of correctly folded and functional, full-length human proteins has a very high failure rate.

The use of misfolded proteins in downstream assays and interactions studies can result in the identification of false-positive biomarkers. The Sengenics KREX technology utilizes the biotin carboxyl carrier protein (BCCP) as a folding marker and solubility enhancer which results in consistent, high-throughput expression of full-length, correctly folded, and functional proteins. Leveraging the KREX technology, Sengenics has developed a fully quantitative protein microarray platform that affords the simultaneous screening of thousands of functional proteins for various medical and therapeutic proteomics applications.

This white paper from Sengenics describes several case studies illustrating how Sengenics microarray platforms can predict the severity of adverse effects that could manifest in patients, predict the right dosage and/or combination of administered drugs, and predict the overall response of patients to drugs.

Offered Free by: Sengenics LLC
See All Resources from: Sengenics LLC